0001558370-24-006460.txt : 20240502 0001558370-24-006460.hdr.sgml : 20240502 20240502083036 ACCESSION NUMBER: 0001558370-24-006460 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240502 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IRADIMED CORP CENTRAL INDEX KEY: 0001325618 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 731408526 STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36534 FILM NUMBER: 24905483 BUSINESS ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 BUSINESS PHONE: 4076778022 MAIL ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 8-K 1 irmd-20240502x8k.htm 8-K
0001325618false00013256182024-05-022024-05-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 2, 2024

IRADIMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-36534

    

73-1408526

(Commission File Number)

 

(IRS Employer Identification No.)

1025 Willa Springs Dr., Winter Springs, FL

    

32708

(Address of principal executive offices)

 

(Zip Code)

(407) 677-8022

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:

    

Trading Symbol

    

Name of each exchange on which registered:

Common stock, par value $0.0001

 

IRMD

 

NASDAQ Capital Market

Item 2.02Results of Operations and Financial Condition.

On May 2, 2024, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits.

(d)            Exhibits

Exhibit No.

Description

99.1

Press release dated May 2, 2024.

104

Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IRADIMED CORPORATION

Date: May 2, 2024

By:

/s/John Glenn

Name:

John Glenn

Title:

Chief Financial Officer

EX-99.1 2 irmd-20240502xex99d1.htm EX-99.1

Exhibit 99.1

Graphic

IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

Reports record revenue of $17.6 million for the first quarter of 2024.

Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024.

Reports first quarter of 2024 operating income of $4.7 million, an increase of 18.5 percent compared to the same period in 2023.

Declares a regular quarterly cash dividend of $0.15 per common share for the second quarter of 2024, payable May 30, 2024.

Winter Springs, Florida, May 2, 2024 – IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

"I am delighted to announce the results of another record quarter, which marks our highest-ever revenue and eleventh consecutive quarter of record revenues. This growth was primarily driven by the continued expansion of our monitoring product line and record disposable and service revenue. Additionally, the vitality of our pump business remains positive, as pump orders booked in the first quarter of 2024 significantly exceeded our internal projections, resulting in a strong backlog of pump orders expected to be shipped in the second quarter of 2024. Operating margins and operating cash flow generation for the first quarter of 2024 remained in line with our expectations and underscore our steadfast dedication to profitable growth,” said Roger Susi, President and Chief Executive Officer of the Company.

“Looking ahead, we are confident in maintaining our strong financial performance. For the second quarter of 2024, we anticipate revenue of $17.6 million to $17.8 million, GAAP diluted earnings per share of $0.33 to $0.36, and non-GAAP diluted earnings per share of $0.36 to $0.39. We reiterate our guidance for the year, expecting to report revenue of $72.0 million to $74.0 million, GAAP diluted earnings per share of $1.37 to $1.47, and non-GAAP diluted earnings per share of $1.52 to $1.62,” added Mr. Susi.

The Company’s Board of Directors declared a regular quarterly cash dividend of $0.15 per share of our outstanding common stock, payable on May 30, 2024 to stockholders of record as of the close of business on May 20, 2024. As announced in December 2023, we will continue a regular quarterly cash dividend subject to business conditions and approval by our Board of Directors in its sole discretion.

For the first quarter ended March 31, 2024, the Company reported revenue of $17.6 million, an increase of $2.1 million, or 13.7 percent, compared to $15.5 million for the first quarter of 2023. Net income increased $0.73 million, or 21.4 percent to $4.1 million, or $0.32 per diluted share for the first quarter of 2024, compared to $3.4 million, or $0.27 per diluted share for the first quarter of 2023.


Non-GAAP net income increased $0.81 million, or 21.2 percent to $4.6 million, or $0.36 per diluted share, for the quarter ended March 31, 2024, and excludes $0.5 million of stock compensation expense, net of tax expense. Non-GAAP net income for the quarter ended March 31, 2023, was $3.8 million, or $0.30 per diluted share, and excludes $0.4 million of stock compensation expense, net of tax.

Revenue Information:

    

Three Months Ended

    

March 31, 

2024

    

2023

    

(unaudited)

Devices:

 

  

 

  

 

MRI Compatible IV Infusion Pump Systems

$

5,192,680

$

5,538,817

MRI Compatible Patient Vital Signs Monitoring Systems

 

6,461,658

 

4,696,818

Ferro Magnetic Detection Systems

 

249,700

 

300,589

Total Devices revenue

 

11,904,038

 

10,536,224

Disposables, services and other

 

5,206,950

 

4,431,741

Amortization of extended warranty agreements

 

487,131

 

507,118

Total revenue

$

17,598,119

$

15,475,083

For the first quarter of 2024, domestic sales were 76.2 percent of total revenue, compared to 77.4 percent for the first quarter of 2023. The gross profit margin was 76.1 percent for the first quarter of 2024, compared to 75.7 percent for the first quarter of 2023.

Cash Flow from Operations

For the three months ended March 31, 2024, cash flow from operations was $3.9 million, compared to $4.6 million for the same period in 2023.

The Company recently began construction on its new facility in Orlando, Florida, and anticipates spending approximately $13 million in cash for its development over the next twelve to fifteen months.

Financial Guidance

For the second quarter of 2024, the Company expects to report revenue of $17.6 million to $17.8 million, GAAP diluted earnings per share of $0.33 to $0.36, and non-GAAP diluted earnings per share of $0.36 to $0.39. For the full year of 2024, the Company expects to report revenue of $72.0 million to $74.0 million, GAAP diluted earnings per share of $1.37 to $1.47, and non-GAAP diluted earnings per share of $1.52 to $1.62.

The Company’s non-GAAP diluted earnings per share guidance excludes stock-based compensation expense, net of tax expense, which the Company expects stock-based compensation, net of tax expense, to be approximately $1.9 million and $0.5 million for the full year and first quarter 2024, respectively.

Use of non-GAAP Financial Measures

The Company believes using non-GAAP net income, earnings per share, and free cash flow is helpful to our investors. These measures, which we refer to as our non-GAAP financial measures, are not prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). These non-GAAP measures are intended to provide the reader with additional supplemental perspectives on operating results, performance trends, and financial condition. Non-GAAP financial measures are not a substitute for GAAP measures; they should be read and used in conjunction with the Company’s GAAP financial information. Because non-GAAP financial measures presented in this release are not measurements determined in accordance with GAAP and are susceptible to varying calculations, these non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures presented by other companies.

We calculate non-GAAP net income as net income excluding:


(1) Stock-based compensation expense, net of tax. Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company’s non-cash expenses, we believe that providing non-GAAP financial measures that exclude stock-based compensation expense allows for meaningful comparisons between our operating results from period to period;

(2) Operating expenses, net of tax, that we believe are not indicative of the Company’s ongoing core operating performance and;

(3) Infrequent income tax items are considered based on their nature and are excluded from the provision for income taxes as these costs or benefits are not indicative of our normal or future provision for income taxes.

We calculate free cash flow as net cash provided by operating activities, less net cash used in investing activities for the development of internal software and purchases of property and equipment.

We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, strengthening our balance sheet and returning cash to our shareholders through various means.

Our non-GAAP financial measures are important tools for financial and operational decision-making and for evaluating our ongoing core operating results.

A reconciliation of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in the table later in this release immediately following the condensed statements of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for a measure of the Company’s operating performance or liquidity prepared in accordance with GAAP and are not indicative of net income or cash provided by operating activities.

Conference Call

Iradimed has scheduled a conference call to discuss this release beginning at 11:00 a.m. Eastern Time today, May 2, 2024. Individuals interested in listening to the conference call may do so by registering here, https://register.vevent.com/register/BIa8e7a7f6a1a54f62b666af525d8cefcc. Once registered a dial-in number, a unique PIN, and instructions will be provided to participants.

The conference call will also be available in real-time via the Internet at http://www.iradimed.com/en-us/investors/events/. A recording of the call will be available on the Company’s website following the call's completion.

About IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices and accessories, disposables, and related services.

We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually


anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

For more information, please visit www.iradimed.com.

Forward-Looking Statements

This press release and any oral statements made regarding the subject of this release contain forward-looking statements as defined under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, that address activities that the Company assumes, plans, expects, believes, intends, projects, indicates, estimates or anticipates (and other similar expressions) will, should or may occur in the future are forward-looking statements, including statements relating to the timing of shipping the backlog of pump orders, the Company’s strong financial performance, future quarterly cash dividends, and the Company’s strategic plans, objectives, and intentions. The forward-looking statements are based on management’s current belief, based on currently available information, as to the outcome and timing of future events. The forward-looking statements involve risks and uncertainties, including, among others, that our business plans may change as circumstances warrant.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made, which reflect management’s current estimates, projections, expectations, or beliefs, and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to; potential disruptions in our limited supply chain for our products; the Company’s ability to receive U.S. Food and Drug Administration (“FDA”) 510(k) clearance for new products and product candidates; unexpected costs, delays or diversion of management’s attention associated with the design, manufacture or sale of new products; the Company’s ability to implement successful sales techniques for existing and future products and evaluate the effectiveness of its sales techniques; additional actions, warnings or requests from the FDA or other regulatory bodies; our significant reliance on a limited number of products; a reduction in international distribution; actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales; the effect of recalls, patient adverse events or deaths on our business; difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services; changes in laws and regulations or in the interpretation or application of laws or regulations. Additional factors which could affect the forward-looking statements can be found in the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) and available on the SEC’s website at http://www.sec.gov. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.


IRADIMED CORPORATION

CONDENSED BALANCE SHEETS

March 31, 

    

December 31, 

2024

2023

(unaudited)

    

(audited)

ASSETS

  

 

  

Current assets:

  

 

  

Cash and cash equivalents

$

45,126,676

$

49,762,198

Other current assets

 

26,758,926

 

26,238,914

Total current assets

 

71,885,602

 

76,001,112

Property and equipment, net

 

9,451,903

 

9,288,625

Other assets

 

6,676,675

 

6,866,361

Total assets

$

88,014,180

$

92,156,098

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

1,285,366

$

1,857,091

Deferred revenue

2,338,414

2,570,407

Dividend payable

7,975,997

Other current liabilities

 

3,992,890

 

3,923,811

Total current liabilities

 

7,616,670

 

16,327,306

Deferred revenue, non-current

 

2,756,435

 

2,793,548

Operating lease liability, non-current

 

1,519,613

 

1,615,080

Total liabilities

 

11,892,718

 

20,735,934

Stockholders’ equity:

 

  

 

  

Total stockholders’ equity

 

76,121,462

 

71,420,164

Total liabilities and stockholders’ equity

$

88,014,180

$

92,156,098


IRADIMED CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

    

For the Three Months Ended

March 31, 

2024

    

2023

Revenue

$

17,598,119

$

15,475,083

Cost of revenue

 

4,210,396

 

3,753,635

Gross profit

 

13,387,723

 

11,721,448

Operating expenses:

 

  

 

  

General and administrative

 

3,991,211

 

3,920,510

Research and development

 

821,000

 

793,716

Sales and marketing

 

3,827,165

 

2,999,976

Total operating expenses

 

8,639,376

 

7,714,202

Income from operations

 

4,748,347

 

4,007,245

Other income, net

 

495,154

 

342,409

Income before provision for income taxes

 

5,243,501

 

4,349,655

Provision for income tax expense

 

1,106,968

 

943,589

Net income

$

4,136,533

$

3,406,066

Net income per share:

 

  

 

  

Basic

$

0.33

$

0.27

Diluted

$

0.32

$

0.27

Weighted average shares outstanding:

 

  

 

  

Basic

 

12,662,526

 

12,593,033

Diluted

 

12,749,973

 

12,686,699


IRADIMED CORPORATION

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

(Unaudited)

Non-GAAP Net Income and Diluted EPS

Three Months Ended

March 31, 

    

2024

    

2023

Net income

$

4,136,533

$

3,406,066

Excluding:

 

  

 

  

Stock-based compensation expense, net of tax expense

 

496,626

 

416,272

Non-GAAP net income

$

4,633,159

$

3,822,338

Weighted-average shares outstanding – diluted

 

12,749,973

 

12,686,699

Non-GAAP net income per share – diluted

$

0.36

$

0.30

Non-GAAP Free Cash Flow

Three Months Ended

March 31, 

2024

    

2023

Net cash provided by operating activities

$

3,883,155

$

4,646,092

Less:

 

  

 

  

Capital Expenditures

 

(478,804)

 

(6,557,014)

1

Free cash flow

$

3,404,351

$

(1,910,922)

1 Capital expenditures include the land acquisition of $6.2 million.

Media Contact:

IRADIMED CORPORATION

(407) 677-8022

InvestorRelations@iradimed.com


GRAPHIC 3 irmd-20240502xex99d1001.jpg GRAPHIC begin 644 irmd-20240502xex99d1001.jpg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end EX-101.SCH 4 irmd-20240502.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 irmd-20240502_lab.xml EX-101.LAB EX-101.PRE 6 irmd-20240502_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 02, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 02, 2024
Entity File Number 001-36534
Entity Registrant Name IRADIMED CORPORATION
Entity Central Index Key 0001325618
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 73-1408526
Entity Address, Address Line One 1025 Willa Springs Dr.
Entity Address, City or Town Winter Springs
Entity Address State Or Province FL
Entity Address, Postal Zip Code 32708
City Area Code 407
Local Phone Number 677-8022
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common stock, par value $0.0001
Trading Symbol IRMD
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://iradimed.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports irmd-20240502.xsd irmd-20240502_lab.xml irmd-20240502_pre.xml irmd-20240502x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "irmd-20240502x8k.htm": { "nsprefix": "irmd", "nsuri": "http://iradimed.com/20240502", "dts": { "schema": { "local": [ "irmd-20240502.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "irmd-20240502_lab.xml" ] }, "presentationLink": { "local": [ "irmd-20240502_pre.xml" ] }, "inline": { "local": [ "irmd-20240502x8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://iradimed.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_5_2_2024_To_5_2_2024_hMZgC-88RUWOYdajAAMyvQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240502x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_2_2024_To_5_2_2024_hMZgC-88RUWOYdajAAMyvQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240502x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001558370-24-006460-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-006460-xbrl.zip M4$L#!!0 ( -%#HEB&^5D*>@, $(, 1 :7)M9"TR,#(T,#4P,BYX M!IHZV\0D4B.IVOGW M.]*B9-JRD@[;DV7>=]]]/-X=>?UA7Y7D.V@CE+R93--L0D!R50BYN9DT)F&& M"S'YZT*#9 MR#1+K](\G9,D:3GNF$$?)8DGR]-I9_FYY5-R2>9T2O,L?T<6RW?9,GM/?G_H M< \H;RU> NY-L31\"Q4CEND-V-]8!:9F'&XF6VOK):5"LT)44*1<59XDFV?Y MA#!KM5@U%GY5NOH$:]:4%I,A_VY8Z0-CCDIP*8@ 1V9,JC1+5-"%VNUVZ6Z6 M*KW!0-F4/CW<_^'%!7 !H@/O5[I,#?!TH[Y3-#AMLP TVB;VN0;3P=?,K#QS M9XH<"J@U<)?92(T/TNI94*U*H#VR\[5ZQ FM <@;K;%PGH?W$*R1+@WKB]Q7 M%*U='M%0V)BYQT:=[(?\*2&R"#6/U>;9;0T3; MC.:KZ?-E;*V'E3I+?.""7T *'@%+5#VR*V=>8?,%.,BFRH>RFF<4]A:D$:L2 M$@<#S2P.")/D;D"TJ5:-M/K2@1^,<6Y,XJILH&Z#)8)+)K@99O>F& SVI>)& M2'_XIYEJ6W.Z6"RHMQZ)OM!LP1+WFM4G^$@-FJDS.Y\\R6;);!H5N1@L\JM# MD8M^LYO7=',+.YH;@Q,CT@][OAW.N;-$T%=,R7Y@73CXSA3W)L85(X4LI+%, M M,G$?WQX_#P?Q1_2IO4K#[T=9_"*ML,^?D597/N"$"-3Y*F0G)$@I8"VD\+(S MK(N,)"00''\R69 #&SFBNZ:G'*?T#=[D7^2M_\:;PR"7]W3CL_5N(6.>G)6\ M*?^%8Z_LLE^[&L[DY*C"2'R$-?%MOW3=>3,QHJI+5RE^;>MO*E^XC.%7RRL%! <7>?Z#,<_?D4-!S26X^W#U,>O#'@[AP'+[#U!+ P04 M" #10Z)8!NC"77$% #K.P %0 &ER;60M,C R-# U,#)?;&%B+GAM;-6; MX6_B-AC&OT_:__ >^[))%T+H]::BMJ>6ZTW5Z!5=F7;:-)U"8L!:8B/'%/CO M9RAZ>6'51S!,V()IN2JY;4[+4 DH"$FTZO6 M(G'\),"X]>'ZQQ\NWSC.U]LO PAIL(@1X1 PY',4PA+S&8SH?.X3>$",X2B" M6X;#*0+P.NWW[6[['!PG][CU$W$.)9":==O>IM+/_2CIP;GKN=U.]QU<]-YU M>IU?8?BPT3V(>!.\3QAA\F]/_C,6 X)HDR2]58*O6C/.YSW772Z7[>59F[*I M.+_CN5\?!D_!#,6^@TG"?1*@%@A]+TE?'-# Y^D<;9V^&K-(&9RYF[&,"OF3 MHV2.?,GQNLZ9UUXE82N/*,L'#*+DJQU]WI-W<7'AIM6-5!B%?*/=]CUWLV)+ M3!Q /G7^&$4#<02I2X^OY^BJA586 M,N4W8VB2^24J8X*"]I0^NR'"\IT^DP>./)#3]I/XX5N?"H)OQ@EG?L"54YK_ MJJ6KR^DX:([=36II=L.*T7T6J,'$X9Z9R!5N0 59<^ZDCNKT":.Q/FHV'-44 MOT7CJ'XOA4882NB"I< ?_J9NYS?-]2:C4,@%!1'GCZ?O"'W]4:TU/@GACG#, MUW!/)I3%Z:<1_E8C_7.9)?H_,5-A1L)1TWFI;#%DND848]LU2Q'31CR:,.G6 M $0W8K!0#O@I\J>:YLIUBS'2MJ(X*A0M!4F?L2Y)&S>0=@VN1T/$, WO2/A1 M;)\J/B]EG<5H5;967JH*(DM1J\YZ].*5V8HK9 C2N 'XLHOQ)QRASXMXC)BF M9XW$8N1,#2G:RG5+03/&K,M8ONN2CI!9-D;7%S3%]H;>QZ5V<]=X;6BN"51%:3 M9\IZ)'JY+:2^((P;@^^>!)3-*4MO;Y^XN);WZ4*$6?=I:%X!]YUE/9@'M5W$ MM/(4JZ$]+/F1"!<&>0OI,$ 9Y$.!'*LQJD?^ZCX4GRD\P=G7J'OVC&:]]23O M:;7(L$%L-;W[,A_)K;"'HG_3N\Z;,!2SEN3_#3!!GG$R]%KK(:UHL0BH1F@U MG%5YCP0S]WRK#D"ZPR-I;A7-!^Z+PTILBOPVB^^7QD MH 9HFM,A3;@?_87GE7=1!O&I,*IM4DMH07D*?.H#O]8*FKF#L&_JKDBNV3<, M^08<2V6+ =0ULGE:8:MF*63:B'6Q2B_$TJTIBN0S2=%P1HGY5S :B<4TF1I2 M1)7KEE)EC%F7K-004L?F;H;_9)AS1/HTCA4-F#JE[\VC>)\D"L>\"5'?*Z6!J;-@ ZX[^-) UQWXU<+,AFN8WN\F^BQ&; MBD7]-T:7?"8:G_O$_$2%26TQM0>T6?P*1BNUE-5#$A_Y)8PRA\P=81[KO8302BU$T-;397I;JED)GC%F7M-0%Z 2\[L_C7T#Y-X#8 MB/GR#^F>UO&8ZEHMURV&2]N*(JM0M!0K?<;:3&5ND-DUN%K=K8*9B(P,#\0: M9!:#5=58>>7:UEB*6674VC?'N2DHUYT'8B_=ER #<23_ #9_*7>Y_@]02P,$ M% @ T4.B6+-\@W:7! \28 !4 !I@P1ZO>-M3"A M\ @Q/G_Z^:>'7TSS^^/+&"#FK4-,8^!Q#&.,P(;$*S!G400IF&#.21" 1TZ0 MCP%P':MM-:P6,,TTQB,4L@^C( G6L-Q#RS"-QV@/M&S7;CB-.]#MW3D]IP.F MDP-N(NDMR25@0.C?/?6QD ,"F285O:T@?6,5QU'/MC>;C;5I6HS[LK_CVM\G MXYFWPB$T"14QI!XV@,3W1')RS#P8)QH===\N>* #-.W#6*4(]@ \ MO(MPWQ DC (U=G)NQ?&R;Q >(E,YX+2:$SBW8@N&0\3 M'0V@XO_Q,CH0(APB$F)D>2RT5:-=+4Z27"7%['UB$<="1DNZCV5CFHT:\O^3 M.1(+;V-,$4:'LR16(SB.TW6 "72@XT-($=A'!?\MQR1#F6/ O R70$U?QK/. MJ7!"QDMB">Q9/GNU$2;J_]14!\K69F*I_/%CR.0Z,5B(F$,OUI$"N,!!WSAI ML]^3AU9K+B.>T#AM_M%NWK<?E3A!U!+N.9WHH$!]>7G(4Y?=*16$7&C"/,Y>IL@+60/%BD&,/@G74>2$Y( M\?H:0+] Z$Q[/92^3#F5NG%=J?4,F&).F%Q7T!=Y(3PSMS.X>DA?G7IJ0?.Z M%NR7W:\DP-_6X0+S O5/(?40OA+K5/.[6VC^@GVBJ-/X&PR+9GT1K$[:5V"> MZM^ZA?Y#F1F'P4C>JVQ_Q[M2 TYP=7*@"O74@O8M+!C)DHM'C"=RS:1J>,C6 MDO)NR%#Y/^)LKSK9\_9$4K,ZMS!K#KB^)KQPP2C!U\F@MZ206G-_ M"VL&"$G=1/HEBSOLEMI2@*V3)57IIW9T;VC'4!X^\SG;T$MF_(NLH147R.LB MSKFA$\G:^LRGG+V2_0;763M.X#7TI$H&VI@KE]<9GE,F8AC\1:*S%_PB<#:E MCNNTNA_=E,O\M257+L/5/WC ,2PQX;BY'K)?9*R%OG*QK7;3@^F*T?)B^Q12 M#\$KL=:B7[G:_I.3.,9TR,)P3=/[.%&@?"&N'O)7IZX]R%?<,IB0GU)_+2QHFBG+,P#ZJ'?Q5Y:_/RM?H' M-V_*L9J;6-Z*)!O^ZOD0?UXN"U? ;>"73CR MWS(M1-?#W+>4]AKMZ.H/YL%RY8T>U'ICU+_%X2 M;WY N2]3UEI?>9M SX.GK;>"U,JW_Q[^Z^#_& :8OX^:9\!P]'"$[ #H'H(!,L#$# 9Y MT'9<%]J@ACS/M"QPY)E&'\5#.#:3R_ 9"3!,/-41]/%(Q\XG/3+!&I>9/.L ,YKBX[1V#-3\Z W2X#(X\G8C*+P^)5B3N)7N[>0-S9U M!$X<#52/\T!5D*KD.)GIR4AF1%&'C"(J'*/R4!%X%N9$EHWF& 0851A=MI\W MD/EC9Q $;CZ;G6J>E?&1GND[XRQN(.L5=J*.\TZ3R20S$3*.U\]RJJIFIV2R MN%/>]$;&O*?I0<,<(2.C.R,*.BNQ?-+3,NWATISTY616GF6%+&G6,&J3[M,[ M_9?60%KG7?%$1K ,5#ROE(T:YUW7@H4[",88%KB23F)815&X%+SK$? 8Y/P#)];3'(? M$CDA-5'2W4.]>Y&>R^+6-!+-!^@S1\KAP0!!X_!@A ((2'<&W83F^,>.[M@! M%BXFF+D8=?&W'SL!F@99RC+9PX/ #"QT>)!-_D93:8XQ.SPPS#'P@YF%?NR, MH- L;SLV(AW,:9[,AKSHHVD8R*8?<8B/+-U+NJE!HV*I;M M$[_2"B9X=F[GD,7L)O!2CE,.LDOK>\OE%K#B,XCR*UNP/U^FT2GDNLH9H[*7 M5V<5X7?%/9&;%UV!++,'+1_=66%V&;F8@Y"'M2[R#P^(3.9]*D-XR8#*:'Y M.9"H"2;1")FI;^S$S819?NSXYLBU$&&0[,J<]*OOA![]1IDT'Z.%PO LM"03 M(4K"Y)MID.\]$WF H'6"GRQ>KI,P=7!A\FCY=E=C#['2+YA6?*"8[Q5'))U M,BP1\F3KDE+\CUY278)40E6YVC,IF3ECER-X)29F ;>&#F6_<^^ M"PVRH3(6Z@7X24:0%L\\LS]8/'1\DU "O\C")!E3H4S-JUL(>GG-"0;[JZ]8 M-])-QO4P$$P/CDQKEO_6QMN+#^IH IK."-K?]J(G^*^/0>]]VZ>]??,6X:FQ MXH@423[6(3[9YM/33A"%0',L(^[*X 4&SB@:/39]4S,M3,68Y?$D?_U;X5EA M_R!+)L/H=C,G@BX#N6 M:8!_L_2_I =5I6N:'T%0M#S<^.G0]92%JZ^[<$@U3I?3-"6G(*F;Z^6,KJBR MJ MU4>O*!E1TC>HKKEQ^T,Y5^[E>9^6D4'EFTPIQ&Z%PU4CXC4V.6 M;I;J;= LG3>:;7#>:;8ZA7K[\TIANP&P(+:QM$6,P0F@T02FT!CGQ2;,E/@[R!5S'",PX,.)OAI2![G8"?4V.T%)FH M*4FO:3/QMMD7;MG3GEA2;8AMTHO^>FJNW<%W#FMP!O@]0!;\=O+/"T\0I[?V M+YNH;_HD*!#4<4L*BZQT5+H5VH'8813;.OG59(HU\>(1?5EM%HZK-6P %!M- MK(0*[?E.^A8(5#<4!'.9_N1SW@SP8!VW[I:F4 \H?B*!2/ "H ]\%^G$^3* M:0,S\($^P#X4\KYCP-Y3N;ZAT)$(%'$- ^1ZSIB@85GJ(G:IVKKC85U W]4B MO8M.: ?>K.@8:>YAKB]#L]RYK0UYI]Z28=AISIB[N^U#,GB,G;4)EOV/XY_' M>89B #@>P%XG=NNO0\_T#5,GR"%,9*:Q]8:\;&+HBF2H@AL MKIN3#+DK0@EU55E7NKJ.?S2-9+K*YR>W0K9U>2F.C0'@Y[AE S4():+$#JCN6!5T?Y9,/ M:7SE,(2#B+M(;"".'29XH*$'& 9.\B"*.] G2^&)M!L=]2%/4I$&O+[ 2Q86 MOY"+J!$8R?,Q\@)3AU9,O(@*\2RB^I\T%>.7)11-13M2DSMXPI[E3!+")=^9 MB0?=O.8A.&0F&$F/1E!B?J O3KI"#?OS88!6H(RB.O&_@?%4\+B,^F<#N+7T MRP8>X=W7@7,[-\/5O:YL6@C/KB%O'LX.E4N.F<%NZJ0Y+E1&G3P=7DRY' M==C3MS:6Y1@A)PGW&Y>O*%.OLDT^Y.,MPQ9Y;G?_G3M KR9-?P:7M>&T&L?V M=3K="LMIE2.]5#EE"L/+LB0=Z76/%WG"RBL3G'N:YSZ4'7FZA M%9W1R/1)\AL0>081=A>VV.<6M =A2^1JED\0-W) MK)"/\FR6&H4?;%QS+S*NM]\OT 56RK%*#W\0M*ZH(J4+)57N<6(/ MK5K[HC:=55CAY^60/_E=SS%BN5*7^_&>NNP7: '3/H*P5S*K#/JI7IP(:-A? MYT$,KSG.#,\:^G#6[DS&PV*%&Q^]A0?QY1Y\N0=?[L$_TG K&(:'?#_^8XU$1?%BM6Y_1V5#L.SF>UF]%FJ+DT"<$3 MM&P52FC(L.&=>\[8I#6 <[Q,SRR^W!'-,FL>#Z]'S&"4NT";Y2W*9U\>Y9=B MBACMW/&Q/7UENHO0/+&VT-DOM7-[I;"\5Q5\4V4\M7NQL3LI\#*K_+,\R1BM M)*Y/U(YNNM ":(KTD.RU^#'V4)#_>3W+%T'_!_N:6$( $9%/ZU2^S#/[L*J/ M>S3'[AMOML3D*&"C>"4A.3Z:V,J9_[?,%ANR:!1_50N3]F:;J\C*+[0TOK^U MI7'F8"D\'SCV4N":(N#2_LKKW\K*.YF5E=.EAF\;_#;DM%? MU#80N>#D?1\$R$(NP0^P*8+V2([6"HE* A!S#:9&6A-\,H#*CH>Q'=#1[ MC[_":&/"H/1(78+=1U@Q$]L26-!/:G?>#J9$E=%'IDV"=7E.R8A+-MX*G,4! MTH<@&" 7==S\'Y*\NB:,P4:PJXM@80T$GBCG4=A3D$/*SM,)M,'Q/K'+S) MX&!(1Z$50!LYH6_-@(_EQ^_-Z/!X@*/A=<(D)T\:4L4=(9X'H]">)6T]Q\(K M(.-('81)(L=^_@W*L*-Z=R7!98PXACY9@S?Z_!TJ0#3'L32(41!@:J15RZ5G M!ACK))X>VG$LUD_IEROGG*N/.B!6+!*,;L/9S+ MB9#A^!3SEJ;1?K7,NB*;B7I^<>^<>\\]1#0O.;1&:]O)]NKTE$^]X?,+K MW(5UU9G!@P.?I2P4_B8HQ@1D]A^&FZF!,-AM_5XG+U)S%V-."+M>]C M[:KOA\A;S^#E4TDJEW^7?@Z1U NNQ$NIQYW'8+) -%:V!4[&UOM&),8*V2V/NA[ MSB08$/RXQ/:&/C!0S[2C NN4K<-*B5V^8NC@IYPJ"&"7=)3WJ;V3=#9I?;9+ MZK.)FY3"-*\Q_)H)ES =S2S.9R8(7XQ+S9UYKZ3])@A:ZN&"TN73<^:'.E0DL8L:-;-3<['\^D2N--)?Q]9(?(2^\!"2!QB+7B M9-[Q6 =86)"%='(-B.U071+ZB/;"*XC]8G++ \WP@NC(-J$3?9?VL64J#1?R!O =IL[!48MI@DKQF:.,C*X]R M$FNHHJ1V94.!75'FE*XBJUQ7%SE>E>0EV[*EQ7AI=!][I_52X?L]U"?'C@H8@*"4XZI-71AWL 2Q 8 M0RM$X/_9#+FF[:&XPL/LO:#*8];(6TGE1HM\U"C<=M:)%7&D@N=\4[NM=AJW MW8[1":>5XU"MBCG8Z<='21[BFVJS=OR/88Y'S:!T7+IZ3>@!%Z)*R(%"#WA %Z7C()RM>_,>> MB/N(2QL3Z):-I'77,J9N;7S$AOIS*/O\Q:8\U'\M.;E0'_8])[0-$IASO'R" MO]1=I+%SS5/*]1$3^="PAY57'EH3./-C%2JKF;E]FY^3@%Q/#*(;4$'J\\)O M_GPWJR;76+**)LHLWS5T5>B*G-KK0IA3NIPN]F1D*&)/TN)(Y^LPPQV#>R6# MQK'K4VC)1<_1Y=:,9F%#;REWOHB0ROPZ(_]%"XYJ/&V21K/6%=U6 Q370/(9 M-BZ]I9S91'YH!?0\0L-%7IQBAK8!RO,L3M&Q#4J@]\U5IC#=L$'J,K4]L.Z& M,&"2G+\!('#I"0O,3 CZ".R2' 411YZFUG%+,VJAS[C][QA:&TN?3LM",2H6 MZ2LO1@Y)>Y%9;D)Z7Q>(TF-XU]0'0."B165 9L*[KP"=.E5)''="SW;] =D MA217/, J(XA(HJH9CN19:%ZX&'K$N\8CZ5UZY,:!=/WJAY&@C6$R[?F=[R3# M3M>[S%GI2N@[,.X!?P MB^8;-00,A$88&S%I>J:%C)@D%.%NZ&'%@"AK+F>@ ME"F31R:=0$,]79.- M'-?5#%[IBIK$=E59YKN2K*DJE\M!11:^U/4&ZEK-D.# 7%TOE#(] 4K*@R)M M'?.6_V'Z87[=ZLO_36"AH'RN6]KH:AC,.$X8#WK-I">VI+@M.=O_?M>C<\^R ML#<)"BMJ1OG"^NMA?:*3[;:2G://-V)R:<[ MS9&BIVXQ*:M+&P!U)_.<#,UCS/K'(.L8^;IGNJ1ETTS%Q[-76JB>*D:?FP>> M"]$64(N8XMM IC,26ID&2P\'M2#/(J4RG[Z17_=A$ZP_^CKHF[[.V#-SQ]- MT515#2XS"$8/%K[I%S^S)ROX';QUIEJBM'K7%[Y1A&P1V^*2$5M6M5*O=#N-,G/;'U,W.@\== @.J-R$YI>'-EZ M:IQWS>$6([1F0('BS]O-T70;82JB]R M;154KV!:O@$X1S/R@YZ;U'F+F;N'<-SI^QW!N0M#UL^>. ,;5"QDV^"+CSZ" MCT@U_$LX*:IE_E V6O#0%PM]! O1TUK/XJ'WC> /3-1+5=@VZ+7?WE?8_2OL MOF4X>Z4<03H"&H?GEV*@R\^(HA?8M:F%L6,:ZS,+BSL"-,>8X3^#8&0=_@]0 M2P,$% @ T4.B6%^G2B::,0 @[X" !@ !I&5X M.3ED,2YH=&WM?7ESVSC2]U?AZYG=3:HHFH=N9U*OQW9F71O;6=O9J>=/B(0D M;BA"P\.*GT__= ,@19UV'$JB)&S59BQ>:'3_^L3UX?_5:E?AD(0N];1_/MY\ MUCSFIB,:)IH;49+ U8F?#+5'-AZ34+NA4>0'@?9[Y'L#JFF6:30-RVX89JWV M\0-\ZT*^Q,*NUCBU3FW3KFMFIULWNZ:C?;G1WGU]O'C/'[Z\NWC\GR]7HM4O M7W__?'VAG=1.3_]T+DY/+Q\OQ8VZ85K:8T3"V$]\%I+@]/3J]D0[&2;)N'MZ M.IE,C(ECL&AP^GA_.DQ&0?TT8"RFAI=X)Q\_X!7XEQ+OXX<138CF#DD4T^2W MDZ^/GVIM>"+QDX!^_'":_5<\VV/>\\UA(V[CCE. MSN#-4[@]]\SWVL3WDF'7,LV_G8V)Y_GAH!;0?@)7#*^Z 251M\>2X=E\$\O>'&?O]5F8U/IDY ?/W7\\^B,::[=THMVS M$0G_H8LK\-^81G[_'V?\Z=C_7PJ?A@[RGQ/*Z>RQP#M+Z/>D1@)_ *WA57'! M#ST 2]=IPBN"1UUX6\/_6S;\XW2:G%M7WX=^ST_^_HO5-,\Z'D T/_/V7MFTZ9Q].\<&/)=)4X)8+#*)1@4HD MS!\-M#AR?SOQHY%70S4Q&Z;]G7[O=#P0K67\=SPXT4@ 2/TC(N.A[YYD='E^ M/ [(<]LOH=* %CKD"!@$\"1MU3<-LP-U%V""ND3*! M+0:2X- (B3_'8^)F_V6'15OU%P6!&0< MTV[VQUD)<,B1.;V289&36P.DLS3I]OWOU#LKF#Y!5(:F)(+_>QG!\K&V1'#B M%6_^%-%/-$I\EP02+1PX0._99.@GM(:\H]V034!CSPI$2!Y+8O_^2Z?9ZIS- MTS7[T(Q^_+PAYQ\"RJ(1"69,N[QT\O&>CED$ (NH"YR%_SS1,*4<3U;+:&K0 M>( X[+.(8[//L?S7+):-7#>Q;ZJZ;[94&15C!UUL3I2!*05Y4 MD#_.S[]HGA^D&.=>?7F0)M>QN=D.65A;]42S,LKSQM!(Z8?2CQ?U8RFV-3:F M&,B$ \T/7382CJ5NM#*_HH/VX"W('V-^TVH;#0U>XD8_Z\\QG(LZTQ;FIZ^0\#@$[9Y=H%V-GSFOZRS]]J[ MV_.'R_-_=^'-F\OW8*)%)HMVV(-&?&[NL^PUDMEK!L)D&%&J 3B38:P!;N&U M&Q*Y0\VQ)/*T1WA,MJGY"/V $K J:-/Q"QXD(0$;\W(DYK_0_!.O5V@C,@@I M6 )LE"$!5//A&OJ7=[(O-_?7>3]&U$.K@1_T,1'/$FP6@G)] X,1:N.(H7IQ M92$\C,O; #Y'!-(AEL;YUZ__DW_<#_MIC*G1.!V!S)_CA([T/!C,OS(&RK$C M3WX"E,1@OF)DCI\PE)]\+P:R2**A+GL4GP&F(3]3<(I>RA^$?B&Q((44.F]L MOXY6M+7CB-:XM04-^"MER=FU1D9 >H#&3?CK##23-9K(QH@TP M-HC8!-Z9D!BX")B)@%6:%\&[H=9[YD3"]R!228%\^GV,E6=1?D%B"@(#&7BI MFVA8A./TR/:P/,=B;F;Q*K :,9>186CGX&9$*3MXUGE['!%@3;)&.(YZ@*F0 MQIB0CX@/6!%%NR<*T(K%(]P#QQ!0L&_4RW1F>?B%4/+[H -A MVEWUU*41^Q M-6Y%@!KLT'^IBZ2!,1&"$O$:Z$.<1 S^[A'W6\ &^-DB!< F>%&(NP?>9^B/ MQU.*ECLC0].TNSPH%- 3BCD-%;G;ZP=LH@UH2&4A;&T.);DE&N>2X<,7V$]! M)/^&:"<-D7B0&>7W0?V(UR?P38];"]X8= C8TO=%Z":PHTO-ARC4]T"U!FB$ M05JZ]@6XABXZX=^_&/JTKUU]SZ!YUP3,&7P&7*$4" Z) M@%Y2;I9 EGW11^ P\CJ!_^-C@H<<)E.? *+L8X0#^F]HGUZ(3K %T#S7!U-) M5U>@0"9XH3U-'682;DHBI"?FT9$(BV3^[?!7,1'7E^?JJU]M9J]V#.U/I TX M%R&5V.M!"FX7+5P&S6?XD"X!AZR!=R.>'5QQP!6)%D!)&O.0QBVG)G6;-#GO/B!;=3GR!$%1T1NIN:S">!2 MYSA'MP-MS'W3;OW@-QT1?XJAP[YS07D-Q=1JN:%K:4&C#AX"5+&]T$ES62?G*:__..5;-=N[FX Q6]%9 M/6C_!FCSQ '_6K@MRGS@)WV/5\2%M[D.>0R,3_"Q^'(TJ[L?53"T<+Q8^]L) MFLB3K S^JMJV( V+A=(3H&7$\ >LPZSE-:=E7FEVI]-9N!'E1>JL5?DU2Q:O M\QKP7'E9=%=^I=$V6O;?BCR:JQ@7;'GA^PR^B2ELQJ3L-\^VNL(138 )+_J' M0J$^?Y3T &M@'^8ZNIFZ+9\[M$RO"^^]'A?%D&&N$K]""JM*_+;1Z"BY5%$N M9EO)I7IRL6RC[BC!5$\PRI!552[*D%51+E;=<.I*,-43C#)DE96+TI?-R87/ MG9F="?53">7.F- >+UG_\UJN;-1R_#1+VB]Q9-WRCFPVS?R_^0J+K/,NPWE\ MX6\GC9,W,L)QC,;:(+T43KRX\.7UO'GDLWUNQ&R?*U[O7&#+46-B,R9[?VV$ MLI;5UXQ=LJ0T&RI+S%GM>OQ=XP5Z+2NR[X^-G1U *MO.'"Z4E.E5IE>9WC>8 M7ONMIM>J&PWKD$PO3AS8%U.[Y1SG[2!I&G7[P$#B*) HS_NBYYVKLIDKBDXS M:M;)U6R.&\JE*Y>^O6QJ?ZSQNS0DJ0>]\=[OBU'^&82HG.BP4Z!+L7:Q>Q X MSL*%$KJR?FQ^RX#9\=?_P14#8DN!+[C*^D%L#5 : M:"O6_3)V 2G#1%>&+:*)7\N+%';0LW6FV5FK_JM6I3=TJV/KS;99=L9?,;EO MWUL?+OQ%&'(@\&\X;;UMM0X6_M7Q!HW=@&8K;-FGPL?2\.B+W$?I/WP?I0>^ MC]+-=%N>LH.E@Q#Z'B>OI64Y%:B:O,WR-_5ZT]*;C?;!#G4H*.]=>>5M4*[K MS4X3@I@#@7)UK/3N"CB5"$\J%JQ]HE'$M)MLY\=+FHA]]50E9V>I[ XG&6T] MQ*E@]\MW)7:]H[=,50Q2&K2!R*J"W2]?@QS3U!OMSL%J4'5\DJHG5:.>Q/>M M.OGXR+!R).?39'M"[GDJ(KM6!;0?3IJ]KQ4CR]([9ETWG0/)LU7)Z'A+1A8$ M*4Y3MW'YS2%@N4*&>G=%H[*9L.=5(]'$97YP1*QGQT;($Q'PH(S#"] KE^(> MAJ4_J#D_MMG4.PU5YE$Z<*P3?^IZW;'T5MU2.G#8A9F?9,,^%6)$$^PZN3E]OMW3+*=W\ M*T4X5$60P<_!*4+#!$4XE+E#NPUZ]K+/>U[EF1E]*GO4J6J]K$)]\U43&1PP MC!Y+<69Y%;S 9E=][;SK&Q@?:.F-3AO\PN%.9*A]W_2Y<@I==<_'V\W!N?F)L!Z# MS^(D]9@$T.*$1E1K-0U;9*/909QX7)[_P83&C7FFWW!XZS;36F!_2^YLC:C9]\N9,C)R_P].=/ 9MH_8B-M+LQ M%8_%^0YHV\);PL\#&#%^'D#A_%-M>@PK/ZJZGQ/+X)^G#EH&N$7/&L].B AGK0=)U$JUGXP<8AV"$WVB*+(Q;[?3R@-I8AVKA00B'",[D1M M/ODA"5T?#-P?*<@@=.G6]26F>"[[HHTKGF..I_FZ(%Z0GCC2?.6!YN)@\E;Q M6&%^1G%VG# E40B0BOD9P^*8;_R$:3@.?Q4/619(#+/CC5]^M9F]VC&TW.VD M0: ]PSMOZ5$+,I"9'K7JTPNOZY%E."W!#*/>^K$>64;#EJ\V;4/;MC'!6,%J MG<6OHG<@83L]')H?!EWK\6.V7WN8M:Y!) LF>IF$5GUO^7> ;3VZ8+"F!IT+ M8N;D[7X!,"((X*C!YV:]N !11&.DRP<[]URF[5JP.E7S\%]CCLX<%%/3=4-) MG )?MF:Z7I-=%KUCCP8^:'>LI3&ZLW#QX'1]";:%TO8QFI@&#'ZL#6DP!K @ MU%@*;B^$+RCX#G+M'>H;;;YAE2P_^TSMX;FNQ)3F9&'*?-#^5H.?0'U.S) M]RAO(Z($D"3I@]02,00=B],Q$(<1 ?P YF;J$V-@(D,OZ 9\/0T2Z#Y6 M8U^3"%J*I2!R5J&_XE\WM-O5C,SY2("$'J0:"=@PKNTS73I#VI]!XBP-/+0= MV W>8!H+_D%S_TU#$4OQSB5+;.4<$?[TY'5#^YVZ)"VR4@ -VG>#?DHGY0 <198I!$H[5)T\$9X- ?OQFF,6.!;F(#$GDCTC/QV2>"F M@0A[N6M<3Z".T,V)U"%[>N94 <-$A$SD]_F442WV0>=)!$@$O@= Y9*.]I[E MP_P#H4\Q%MQ>?OHGS7E EYD$['#AE_!O6"]9.(-OF&^K/BVXS%E>%V098=5F M>#9[0V[$CGD[VN!:MC'[7,G!F?9%C&98$.TTLN$T>?#\[+6$C<5K8S*@-7%: M(H'(.^J28$*>8UDI:G6,Z>0%<B&:.4+PO;/>,0UQBF/BC,KA[,;;3P/FP21_;T.(#D,101HF<\J/ ACB$)@"1W-1(FGA C,H!C+,["[.G7T3W' MTNNX+ ;)P^T>A"]]K"(L9Z@(G(!- 3[<3WG3JQO84N(TXT;F@D7I0?@%&2D) MMY=+GJ ) %.'$(,(KO!\%GV(\'+VV3QGF2FW]'ED%O&8B_63"9&2&:>1.P2Y M\;@/R(#&<88CW$'+PE_>3A'FSRF4YCDETS8M\($D#\V=-$!%4\4#>(H&I1!> MX:M %O@XS@7L5AZ1:Z3'TH1SBHPP7D8.\$9%I)Q%(0"L'J8&*(#4BJZ%%% >RCB-B!?IAX\31E"W@=1-=8]63H8/LH7&V5E6/@-62C7ZIKD'4\ X TJ':IDU I[ M*KW)=CI_CL57%F)A-9]0S*N>:QB2*?=,H ]"Q?=&8 Z+,?5L I9I_K0,(9UD MG(&VC^%GEO?Q,3,-;5.TT)X_&E'/%R62/D/'C;S#MS#!0K^'HX]P7\0<:('S M0KDQGR$NZ:1,J?(L(7$-ZB"A7W@*G;L J*OK4#^.B(>O.IIX%:TV!U2+\4<#Z/0 MG!APBKQ$XOFQFW*[6H!>#\Q@R,T9&%O+ZIJFB$2(,3+$7ULMVZS]7/1LFR3CNGIYFS1E/6&Y.#(!8?NWT]VO2 MIBW2ZC>)11KU?M/N-9M-TF_8#:_MTK[K?CA-/R[09YHMTUVL[JV_^T/4&[S= M8M5M]N-\#(6G[G?(Y:Q#'!-@8H(:B"5,1ST:08:C@?>$:%/[.WDUH$J&&Z!M,ID8OE16#C4:UM+X- ^03CD(XU,4KZ$)3Q;Q<$9:W6F_ M9[HL$H %FSRA/8AJZ+PW(5A8=SKP +JU@/*JV":M9;&28EGKO3>/$*_OSR^O M;ZXNM8N[^R]W]^>/UW>W)1+X _0LHP2+SA :B_(JH$U&_2+6#-F3\%KYKG_W M%!)M[NFN1V2 3V5%WIO[ZZS&*R(,417$,,#E01=?^6UH?V)F$?N#$&/7,.V# MDTO1,@+9WV@BE!;L>A+Y/?37\-G:ZL\)+^O"7S&+>-#L%=>;B^@VX+%XMO:\ M3'#\ .__%*D\8I:%$!1]"]DDS P1'T7_\G9[&? M':8QQL,T8KX%(PZJNWX?&00M""X+(]?#J01]$?U@/9H),5B-"P(I0UZM$ 8!$]9PWSQ": SF.\!_=&$+'A8, (1TBDND. M-,!<@J>-$0,)C?**[2J"'B"H]TCDS787=3U,"* UYQ;/. ,(6B,6PD]$# MG MRUDN&%( %%HLILFBA/LL_'MFBK.@3="*K,=LB =D- M[!P, M4" ;B4C,NSUB8'AUZ0.+$, 7^KA_)_0('9[4#5E/1]2 3O4IK[CP/B-:@FQYDTLVQQ7JJ<#;Q3+$AYH)[GX!"K M4S+BU0H^SDKXP"U6"4.NTZCL*4I#YR1*$1VQIT)9RH_ 3R<\ M5Q%!/P8>V*X[] ,/8";#DC[)OC5*0=&FPVNHJ]3C-HM/(!@AT"&?8CT_R#6W M0/Z6#)I,Q9UVVYPWRI(SLM\QW[Q^--V\O@#='E9G0"=&9WD2PKLK.R#M0#S%&Y_KE!/?]VD X$_'2*!CZJ9I M:@.2QOE@+:^::+XP1YE5>?*C).6"5V,_^SSV\P.Q #C%"::#F4?)-!DL@!8Q M-EJ&06'XN=*Y$"4%V(X(2_-PBF2!L<_-%P\?@NFH+JL>>@:@B8XL=D&J<&XMI)N>9:>HK6*]!LL&X&VN+OX0K/*>0T" MJPWP>G$2#*![R7 4G\T:-BRI0;($G7^& MZ-L^PY(NO/A$\\E;^85>P!CWNC&6J,YR+H,)XB8CS6:/L+$L:!+O"4-R#SP) M2*DV0*@(!\U#HP&^S84K>"**FCC!(^7VSP_]43K2SH,GRB"&@\PKQ F?43:V M.)T:L R8;_8%8 /AT\]@3VH\).4H%A9].M"'DJ/]OJQ&0CLCZ(B;UT*7M397 MOW=!,2&_+[E>_0/:CI,&1XQK>TZ8KHU%L0K'EXI)_ ;G6,WGZSPOKTBFO*,) MLBR:0')1^\P8'PAXR O2)<\V6Q]6/6+UDNO[=%X.GRT-J5.$L)[6R4>0IF,% MC(A""I]B*P;[A9F;ED%%I3/+D_JRIX'L:>&3!..9/I_MP_FF/W6>68[ MX5(:B='!<]&4U7$MJR6O7GUWAYA7%;Y1+W[# !-4[*TN MXS^(_\.YP0+H*!H4M/M80(CEN#D$"YR-A=%,?KTX]9//B,#BP#@@.$(FIX+J M^40^74Y"PT1(,P!WO-2EYZ- M7*!1 !_&,'C-X@ Y[(R.;+7 BN."!::(@&9:ETXP!^>EMGCHC\<96M"?!XQ? MYQD8#\]B?6G%+<9D>E 8?2D,AN@9L7("*SAI/I#!Z^;3>74K/BN'*J4$6#9; M)FT@>E(;=X6,#="_\!EV]>GS\H;F$(4:JT%^TSBC),L M3<24+>Q/SE79?5'C?)%.<.X,5RA$?OQ-I#8I,#%"W9P;Z]4Q#,(F$$<9KF<& MD3G7.'BD.@&IKA^YZ0@:#+$H)G<:VEYBN&IU6Q66MZVG_)X7/N54%,*+$50, M*^+00$!YZ]$]$^ M%K#6P3@W/;EI$J/\PH9E\RWY;!?$N]0G6=U8#T%9)^.V2_S&EIB:/?K&D#8$A[/%2U>UD8V,"!-M0S206W3)!]+ MQ>*BJ(U :,RXIE8-G/EIHH(M I MZB\NQ=#SJ_& ZS^8F+Y[&:4#[=P#8^#'6:"<%6D_79[G5=J&9;[[)F="\:R4 M0PB)P!53&1%9211_8&W \Q$J0%L:"LGR&7$QPLL#,__,/8^'%:Y8QL%+,$,2 M:471XS'7YP6E/!E<4H+'C^)Z23%$/7D]B_R1G(,-K.:E>"R&BI67"76'O!@I MHGGZW9?3C7#*13[):LH$.06#SL;]W.SA%"14^2 M4P2>]>32.)XJ\SE3V;R3;%0#?IYEM&:87T]343LY!'1!!I=9RM?2Y0 JS-LJ MRI?[+2%A*5+!7R0 0 Y:C%9%YE.040*X,O?&X0:IXU!,JR\XHS.N^+Z+>2>5 MSW& RHAFAA9)('>OLW2AZ,7XC_2NB+\B7F9 DHWDG$D'R%L+R"26XSV#;.JY MQO+0BDL"8K%D.C$$K$(AD^3OLZCX.L2C4V@AL3CK2QA3(8FB(5OM^Y=-G5G0 MIC 4MI:O%@.*(#49:999^Y=>B+#$[;AX_]_"Q&<.8OZ)=NU?6+\H:CXW9(6H M'%_/(W.@:^3S>%5[AP]+D_9P=9&;-)Z:S _6R@=F!FH!L(61XIBZQH ]B1C_ MM1%=,96?M@DF)XVSEKE3Q6(:ZTMO)R<]H[> T#+P!WDI(!WSIU>W7HV(Z;6[ M%ZA*\7Y6BI>7.,3>&UAXH]$L5C8\@>!'R;FXN[V\NGT >GX__WQ^>W&E/?SS MZNKQH>);4J#4>:=^.T'8P'?%_,5,;P3\0#4",HYI-_NC2!H>,B2U ]&"Q17@ MSRP:S>GF)Q**>*4 +&PXU];,/HB.OG('N(917[O!7P'?A>_CBGF<#ITQ*?O- MUS1VA7).@ DOZHSD/6\X>Y3T^% NG>OHEK=]F=U7Y0UF]"?W5S(Z2BY5E$O; M:%I*,-43C&/8+267ZLE%&;**RD49LHT*YD>WXGTI$*OPKG<)5A0#P!B$P_;) M6S<"-%_ 8^F;0R[D(TM8LFXW)KY9ERC'.I:>;4[>*V-7Q)>C@\^/YP#(4**]Z*AN58>)L9J-I^V^LZ?O[PP <$2M$ 48VH6O=_ MPC#^5/)?L=,?%Q@S:P1*,G\5$WYYAUHI:.\]M/M69_$PVWT*DH4UOQ.[ MA\^$RN4!^2A.;&Y7K:)?$L[!QK<:;;UCEV[GC]*H*UW8;UVP'= %JUZ2S:^, MCY\YV'I3?J JG=T0W \AJFE9>KO=T)NFK:+Z8XCJE1(L4X*F;IJ6;EF+2K!/ MH;UHXLO28PKX,1P'46DL&\'[!]>.7F]8>LSOXPW0%91W"V6[W=:;=N/0 MXFNS4&;9?%B]Z\QKQQ''KKM?OE[P.CO\?U$O5%2N=$CIT.MTJ-ULZD[3VNN@ M?J90L]%"O0,R]UB*NP94 ?-ECC_MNI_E@QNB)M.JZU;;5$F 4H0C5H2.K5N- MIFZ6-BRK(J0JUBV/:=INM?B@\@:E%0>K%?N4"<@FUJU,^GQ]_OOUY^O'ZZL' M[?SV4GMXO+OXUS_O/E]>W3_('0RUJW]_O7[\GU)7+QU2:KP'\XE5@*\06FV$ M'D3DG2TD"GRQ&[1/2UQ-5+&^'OBT@.T8UHK)5,7("MI[&>B**>KGKHL'IN&) MGL^XE>U!Q (EUO+VKU1GZ7:[H3M--;%MUY>LBU QM%(6I2QSRM)HF7K=;.UU M^5FZ!WD"XD%%Y4>Y><7;L,Q'$>S2AQ>/3/H*\?N#^);>:37T3JQ='T<3=F$8DP4/> TIB MFH?9SQLR\<>4<1Y<>FGI#:L#4;O:-4:IPM&K0M-JZ.:2M=-['O#/%%]4+5_5 M(=^D'9;>[D"89"V&2"I-4$JDE.A5:8:IMYR&WG'*VCEXEPAX2)C[;<@"D%&< M+2/%G25!5U0-M&(UT!6=4VM(%4+W"Z&'%(K'*PVH"BI44/'Z0=>F;MF67F^J MS=I59*Z4Z,TG'M0A.K>:^QV9KRKU\&W?M^%O=KV5W)86*.Z\GVKOR(K[C%T# M1"G"IO:./$UPB1/\U_.?RI?6/)6%!_/G+UOZ5H%9T%CY;W!_MM4:!2UO\ M.XRRKTUCHYK+ A9U,]B[ 241*M'P;/;&4#2-' G\D-;D;W..9T,'=FU&4+&+(9H@X$FTH D_A.=^VZ!*?--+'NS'"@L M"+Q@,5P: G]FT7)]?WYY?7-UJ5W'5S=?OXH-U]TNZ^7 G:'DHD[@5:UNXR^.YK2%(/3*KW/M]&<#M4K57O MMULB!"YO];<31#XTQ U_KOI"@T"[ S*.:3?[HT@]+J:2"HZ =^$.=&!6H0J> M46H37BGH!C:<&QSY-4OT_)492A<1[<<$,XZK3=X@LU6D)5<=B,7QS#75L.57':D M+W6CTU""J:!@C&9=R:6*PF/UI4%BM,X9J=T]&;9 ?DS=!>2[<;)6\/VIE'?+%Q*YLTG M%@EF)$,J_G@<1I1J-_#H,-:N0H]Z6FEG,JRW;)LOU6Q/N929J;Z9J1!GNU9 M6ZJJ6M=_/'Y^.VR:1FNWJUC+AXVC7-:67%;%)@O?JXWJRS[QTZS>$8^ES&03 MQ=B#V,?$:NF-3ENWK$Z9X1=ZS(H)?A?S.G$LI6)L4/B?PW]#K[=P$X<2]S,1 MKK]B["E/(?8O0;U@<:*Q?NEGT1R7/9/^_"@6,DD+=W"KENJZ;9FZTRGQ[+2- MY\<55 7IVI4J[+$J.'JKX>C-,G>QW'K.7SDO7YEH5ZYK_"-B<:R-(];W#W:/ MV@IE]KNV$ENUB-7K_@;2(T=WVBV]99>;'JGRP)KRP*Y1I)2H_)WP6KC?QI+- M@E6-X5!J#---E.GW,0UC&A_&IF:[BBX.R--_A="]06C5>GBL M6;DX*_(/&H*O#/@60\0;^:$?)Q%?W:!2](,>?-]"]K!_V0&>>6GI]I+S^E2& M?8 #\$H'5IQ9:>H-J\2=Q%2"7)D$67C]>QI37"' W;Y'GVC QJ,RSQ4Z+N.F MLN3=FZVV;>FF6:[14LFT O+6@8QGV;6L%J)R[&F&G\+X/))";^L)3WR@6 MJE6RK<;#U5#>CR8J;;NE6\UR)PVI9%T-AQ^/#MEZI]/1.ZW2PPV5[%<@V9\Y M4( M#(JK;%_-O3_2"<=MO>ET=*=DNW>D]8)=PT.IPD_5&_265==ML\0#J%3% MH3(IA P!KD.7C:C6C]@H"P18N-$SI(_+$*HA_GTQ=W6]56_K3KVEJ@9JB/]H M=< T6[I=+WVY7<6XLXLH8!6#JC M/AG22/-Y**!K(57#_:H <*Q93[W3T*W& MXGFA*OU7Z?]1*8)3M_6Z6>Z.4RKYKT8(/)O\]VB?1107X",+6*C!3QD-: GY M7N)X0&48H,H!*A5:;_X:D 8Y>L-4,_Y5.>!8=:"N._6.WFRH: 5FZ93;U3K/<'4%4,4"IPMZI0@=CX;8J!AQB,4 T<4L3 MZ?U5MK_Q;'_60#A@(#R6XBGT5;"&F]U]?.==WT2:9#E-O>&H[?=VM-Y *=!^ M*Y"CUR'0-IMJL<'AUAFF\84VII$6#TE$U>9[/Q-7'%+&5"FM5)OOJ?T"C@VA M5>OAL2;CY"-;W9*\4'D(Y:M-YNVWK#57GN'GI@K;7B--C0ZCFZ6 M/(*EU +:3Z!;AI/'^36N!G/7$C86KXW)@-9Z$27? M:J0/<.N28$*>8ZG%K8XQS23%)1.9!#W+>C4BW^4=RS3_ENGT#!W9M1E"QBSV M<6OI;D0#?HKTW'<+3)EO8MF;.]*^/=*W-^"X'+H66G^!R]?WYY?7-U>7VL7= M_9>[^_/'Z[O;'9)S?W5Q=WMQ_?F:$Z+=?=)N[VYK?YR??]$^7=^>PZWSS]K- MU?G#U_NK!VV'A+[[&I+4 W_LO=\(JKC[1%C_A//7APVEO1WKY=A."EI-SY+<3-+W0$ ].%.\#<68M>"-ND.<.,#><>3W[-$CU_99VF8;2;ZVI4 M!1]1^#Z#;_8#-LF8E/WF06Y7.+@),.%%OR-YSQO.'B6]F"$ZYCJZY;QO-FIZ M0RCRLX45>^VXDI++;N1BO[#V4\EE-W*Q6L;:D22R M.;G\Z##F2^'Q(0Y&O&2R=R'XMY0%)1,@^8).0J;6.'DC0^JFT=["M)9U>?82 M'JU+NQ^'$:7:#=P8QMI5Z$&FG:?92@^4'OR4'E1H>\V?U9,;$KE#,8SI6'HV MGJD49>\499V0BW.Y9^=U]U9HB/U6#;$Z1MT^* VQ3;N^P"@%DY^$2=NP#@XF M3AF&LV(S@4K=E5?@OV(]W+ZWL*NX=*^4I! M_M7[X>Y?-G#UW0W2LA:?[SZ"*VW*Z4OU[T.T/2^-D>W_.EL%T/T&Z N#'Y4! MZ)XG-TW>Q$/"W&^U'HDIYK0C/&Z,X(!/=O08/XI<8_V2CR.K9"!8LMJ^N)*A M6@KO05)B37'7W=Q$A;'I.+K5*'$1I%*#PU4#X>UVW8HHFLDTQ:ZLWQ=10)RSK3/-*VYNCD@%RA88:=JY'V]E4X'4I MYD&8D4ULS:&T2&G1J_/,0]&B53MS[%.N::Y*-:EU4:<(@:<*CY)VB N;WMEE[8FV%O-U=2I![IEE6[IJR4K5D^X5JQ"Q(/ MM4\!FZCM6':Y'8MEF&H;@PHNRX8XIZWD4CVY6)W"/GM*,-41C,,7PBFY5$TN MRI!54R[*D%54,/8+AS@HN6QU0Y:7 N1J%]E*V(.AB7L$[]'*X!>W(MF89NZ$ M%6LSW$T>N*(4PU@XAFFOE]3?O+@WB=(R+\BO:%S. ML'B[<@PH92!F4TF]CEGV9'+40C=#X1N M/5VJG%>H3' D]H*Y(&,_(8%VA=N\>'Z21IO-@W9=1=BF(E>P^V_7C%71Y+MZ MJZVWS?I[E4QM*YG:-8B4#I6M0TV]T6CIIE6F%NTL)UO+CCB=;82_UC+@B;.Y M_B4,>6-].(57YK1O\<%#S>;D]C%\IC:O8?;Y3.VR;,NNU[5LJVRSZWYN9JO: MNNXTK++=[E'ZV%WC0^G!FUVGI7[L]^J?CBM/A,"\5GW+(F2#VJ)4.J!23T-.+^E?IB!01N2OYKT[ U MZ'0 OXT/I_YA#"+MS$0=AMZII%>A7:']^!+;76U6X^3/J=U)]I:R&^KY1+N M)XB;=#?5RO7]^>7US=6E=G%W_^7N_OSQ^NYV4VV]JYNM]UJSU:JU3=O>F$33 M[)M M+X]E8?S__8AX0*1GN&STX31=7%87P-N807 8G$ MU>3OK"0JBDV667 B8V6L0_78=85@'M":6^Y)^0J,N>6+0+V&&6YW"DC5Q MR42^GO:8]PS_&2:CX./_ 5!+ 0(4 Q0 ( -%#HEB&^5D*>@, $(, 1 M " 0 !I&UL4$L! A0#% @ MT4.B6&'!U.S]$P GXT !0 ( !%PX &ER;60M,C R-# U M,#)X.&LN:'1M4$L! A0#% @ T4.B6%^G2B::,0 @[X" !@ M ( !1B( &ER;60M,C R-# U,#)X97@Y.60Q+FAT;5!+!08 !0 % + $T! 65 ! end XML 18 irmd-20240502x8k_htm.xml IDEA: XBRL DOCUMENT 0001325618 2024-05-02 2024-05-02 0001325618 false 8-K 2024-05-02 IRADIMED CORPORATION DE 001-36534 73-1408526 1025 Willa Springs Dr. Winter Springs FL 32708 407 677-8022 false false false false false Common stock, par value $0.0001 IRMD NASDAQ